You are here

  • Home
  • Archive
  • Volume 68, Issue 6
  • Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies

Article Text

Article menu
Download PDFPDF
Letter
Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies
  1. Y K O Teng1,
  2. J Tekstra2,
  3. F C Breedveld1,
  4. F Lafeber2,
  5. J W J Bijlsma2,
  6. Jacob M van Laar1,3
  1. 1
    Department of Rheumatology, Leiden University Medical Center, The Netherlands
  2. 2
    Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, The Netherlands
  3. 3
    Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, UK
  1. J M van Laar, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; j.m.van-laar{at}ncl.ac.uk

https://doi.org/10.1136/ard.2008.100438

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rituximab, an anti-CD20 monoclonal antibody, has been approved for treatment in patients with rheumatoid arthritis (RA) who have failed treatment with tumour necrosis factor (TNF) blocking agents.1 Previous studies have demonstrated its safety, efficacy and prevention of radiographic progression;2 3 however few studies have yet addressed the timing of repeated courses of rituximab. A study in 22 patients with RA showed that treatment with repeated courses of rituximab over a 5-year follow-up period was safe and well tolerated4 and additionally an open-label extension study of 3 large randomised, double-blind studies in patients with RA showed that clinical efficacy was maintained with subsequent courses of rituximab, comparable to the first rituximab course, without increased additional safety concerns.5 Interestingly, one …

    View Full Text

    Footnotes

    • Competing interests: Hoffman-Roche provided free supplies of rituximab for the patients included in the study.

    • Funding: The study was supported by an unrestricted grant of Hoffman-Roche Ltd. The work of YKOT was supported by an Agiko grant from The Netherlands Organization for Scientific Research.

      Ethics approval was obtained.

    • Ethics approval: Ethics approval was obtained.